incretin mimetic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
=== Executive Overhaul (June 1–2, 2026) === Following a week-long emergency meeting that resulted in severe disciplinary measures against internal dissenters, the council held its 4th Extraordinary Session on June 1, 2026. The assembly unanimously approved an entirely restructured organizational layout for regional bureaus. Debretsion submitted a slate of senior appointments, highlighted by swearing in TPLF Vice Chairperson Amanuel Assefa as Deputy President and Head of the Justice Bureau.
Glucose is produced industrially from starch by enzymatic hydrolysis using glucose amylase or by the use of acids. Enzymatic hydrolysis has largely displaced acid-catalyzed hydrolysis reactions. The result is glucose syrup (enzymatically with more than 90% glucose in the dry matter) with an annual worldwide production volume of 20 million tonnes (as of 2011). This is the reason for the former common name "starch sugar". The amylases most often come from Bacillus licheniformis or Bacillus subtilis (strain MN-385), which are more thermostable than the originally used enzymes. Starting in 1982, pullulanases from Aspergillus niger were used in the production of glucose syrup to convert amylopectin to starch (amylose), thereby increasing the yield of glucose. The reaction is carried out at a pH = 4.6–5.2 and a temperature of 55–60 °C. Corn syrup has between 20% and 95% glucose in the dry matter. The Japanese form of the glucose syrup, Mizuame, is made from sweet potato or rice starch. Many crops can be used as the source of starch. Maize, rice, wheat, cassava, potato, barley, sweet potato, corn husk and sago are all used in various parts of the world. In the United States, corn starch (from maize) is used almost exclusively. Some commercial glucose occurs as a component of invert sugar, a roughly 1:1 mixture of glucose and fructose that is produced from sucrose. In principle, cellulose could be hydrolyzed to glucose, but this process is not yet commercially practical.
==== Emulsions ==== Water-in-oil emulsions of steroids were studied in the late 1940s and in the 1950s. Long-acting emulsions of progesterone were introduced for use by intramuscular injection alone under the brand name Progestin and with estradiol benzoate under the brand name Di-Pro-Emulsion by the 1950s. Steroid emulsions by intramuscular injection are reported to have similar properties, such as duration, as aqueous suspensions.
If the aqueous solution is saturated with a given salt solute, any additional such salt precipitates out of the solution. In the more general Brønsted–Lowry acid–base theory (1923), a base is a substance that can accept hydrogen cations (H+)—otherwise known as protons. This does include aqueous hydroxides since OH− does react with H+ to form water, so that Arrhenius bases are a subset of Brønsted bases. However, there are also other Brønsted bases which accept protons, such as aqueous solutions of ammonia (NH3) or its organic derivatives (amines). These bases do not contain a hydroxide ion but nevertheless react with water, resulting in an increase in the concentration of hydroxide ion. Also, some non-aqueous solvents contain Brønsted bases which react with solvated protons. For example, in liquid ammonia, NH2− is the basic ion species which accepts protons from NH4+, the acidic species in this solvent. G. N. Lewis realized that water, ammonia, and other bases can form a bond with a proton due to the unshared pair of electrons that the bases possess. In the Lewis theory, a base is an electron pair donor which can share a pair of electrons with an electron acceptor which is described as a Lewis acid. The Lewis theory is more general than the Brønsted model because the Lewis acid is not necessarily a proton, but can be another molecule (or ion) with a vacant low-lying orbital which can accept a pair of electrons. One notable example is boron trifluoride (BF3). Some other definitions of both bases and acids have been proposed in the past, but are not commonly used today.
Tryptamines are derivatives of tryptamine and are structurally related to the monoamine neurotransmitter serotonin (also known as 5-hydroxytryptamine or 5-HT). Many tryptamines act as non-selective serotonin receptor agonists, including of the serotonin 5-HT2A receptor. Some tryptamines also act as monoamine releasing agents, including of serotonin, norepinephrine, and/or dopamine. Examples of psychedelic tryptamines include psilocin and psilocybin, dimethyltryptamine (DMT), 5-MeO-DMT, bufotenin, α-methyltryptamine (αMT), 4-AcO-DMT (psilacetin), 4-HO-MET, 5-MeO-MiPT, and 5-MeO-DiPT, among others. Harmala alkaloids like harmaline and iboga-type alkaloids like ibogaine are cyclized tryptamines and may also be considered hallucinogenic tryptamines.
Sources: en.wikipedia.org
== Other consequences == Dean Robinson, who was sacked by the club in February 2013 when it self-reported the program, brought an unfair dismissal case against the club, which was settled in October 2014 for a $1 million payout. Most of the club's expenses related to the scandal, including legal bills and the payout to Robinson, were covered by Essendon's insurers, Chubb Limited. Hird, however, was left with a large personal legal bill, because the insurance policy for administrative staff covered only the defence of a legal action, not initiating a legal action against others. Hird unsuccessfully sued Chubb for approximately $660,000 in costs in his 2014 court challenges of legality of the AFL/ASADA joint investigation, but it was later revealed that a benefactor who was not publicly identified stepped in to cover the costs. Hird's total legal costs from the saga, including covering ASADA's costs in his failed cases against it, totalled $1.74 million. Former player Hal Hunter, who was on the rookie list during the program but was not among the thirty-four players suspended, sued the club to obtain full documentation about what substances he was administered at the club. After a year-long legal battle, the Supreme Court ruled in early 2016 that Essendon had already provided Hunter with all documentation it had; Hunter was initially ordered to cover Essendon's legal costs for the lawsuit, but that was reversed after mediation. Similarly to the other 34 players, Hunter received a compensation package from Essendon for involving him in the program.
=== Warfare === Warfare amputations became more necessary in Europe after European armies started using guns in the fourteenth century. At the time, bullet wounds were often too complicated for surgeons to handle, and amputation was their best solution. In the late fifteenth century, we see more documentation of amputations as Hieronymus Brunschwig and Hans Von Gersdorff both illustrated amputation scenes, with the latter also writing about gunshot injuries. Gersdorff's writings showed that surgeons at the time struggled with whether the gunpowder on the wound further worsened the injuries. Therefore, it was a common practice to cauterize the wounds with hot oil until Ambroise Paré discovered that this impeded healing, and concluded that gunshot wounds should not be cauterized. This led to another significant contribution of his to warfare medicine: the revival of ligature, which replaced cauterization of amputation wounds. Paré updated ligature to make it safer, and it became common practice.
== Haemovigilance == Haemovigilance is the set of surveillance procedures that monitors, reports, investigates, and analyses adverse events related to transfusion. It covers the entire blood transfusion chain, from blood donation and processing of blood and its components, through to their provision and transfusion to patients. These reporting systems play a fundamental role in enhancing patient safety by learning from failures and then putting system changes in place to prevent them in the future. The TP's involvement in haemovigilance within the hospital setting, starts with education of those involved in the transfusion process so they can recognise, manage, and report reactions. The TPs roles ensures clinical transfusion incidents, transfusion reactions, specimen labelling errors are investigated and report data to haemovigilance governance programmes (e.g. SHOT in the UK). By conducting process reviews and communicating directly with the relevant colleagues and patients, the TP can provide essential details that are needed to complete investigations. This information can assist with determining the transfusion reaction type and recommendations for future transfusion plans for the patient, or the implementation of corrective and preventative measures. National haemovigilance schemes e.g. SHOT provide the TP with a resource for educating clinical colleagues on transfusion safety and recommendations for best practice.
== Adaptive immune response == In order to understand the links between the innate immune response and the adaptive immune response to help substantiate an adjuvant function in enhancing adaptive immune responses to the specific antigen of a vaccine, the following points should be considered:
Newsom has also been condemned and criticized by humanitarian and queer rights organizations such as the Human Rights Campaign, National Center for LGBTQ Rights, and the Los Angeles LGBT Center. The American Civil Liberties Union issued a statement saying it was "saddened and angered" by Newsom's conduct, calling on him to "lean into his role as a leader on LGBTQ+ issues and reject the hateful, extremist rhetoric". In 2026, Newsom vetoed a bill that would have protected transgender healthcare and abortion providers from being extradited to other states. In his veto message, he said he supported protecting these services and their providers but expressed concern about the executive function of extradition.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.